August 11, 2015

Three years after it launched its EpiPen4ASchools program, Mylan announced this week that it would continue through the 2015-2016 school year.

August 10, 2015

The Food and Drug Administration approved Mylan's Lidocaine Patch 5%, a generic version of Endo Pharmaceutical's Lidoderm.

August 6, 2015

Mylan on Wednesday announced the U.S. launch of its generic version of Nexium (esomeprazole magnesium delayed-release capsules) in 20- and 40-mg dosage strengths.

July 9, 2015

 Mylan announced Thursday that it had launched its generic version of Valeant’s Targretin (bexarotene) 75-mg capsules.

February 2, 2015

Mylan announced that it will acquire certain businesses from specialty women's healthcare company Famy Care Limited for $750 million, with additional contingent payments of up to $50 million. 

September 10, 2014

Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global. 

August 19, 2014

The Food and Drug Administration has approved Mylan Institutional’s application for its dexmedetomidine hydrochloride injection, the company announced Tuesday. 

August 11, 2014

Mylan announced the launch of capecitabine tablets USP in 150-mg and 500-mg dosage strengths, a generic version of Xeloda tablets from Genentech.

May 6, 2014

ylan last week announced financial results for the three months ended March 31, 2014. The company reported adjusted diluted earnings per share of $0.66, compared to $0.62 for the same period last year, representing a 6% increase.

April 28, 2014

Mylan last week announced that it filed suit against the Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on celecoxib capsules, the generic equivalent of Pfizer's Celebrex.

April 21, 2014

Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court's decision on Teva's appeal.

March 25, 2014

Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution.

January 8, 2014

Generic drug maker Mylan has hired a former Pfizer executive to its executive leadership team.

December 18, 2013

Mylan has acquired rights to an experimental respiratory drug made by Pfizer, Mylan said.

December 5, 2013

Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

November 14, 2013

New legislation signed into law Wednesday encourages states to adopt laws allowing schools to maintain a supply of emergency treatments for life-threatening allergy attacks.

October 31, 2013

Mylan experienced a slight dip in sales in its third quarter, due primarily to fluctuating currency values, the generic drug maker said Thursday.

October 17, 2013

Generic drug maker Mylan has appointed Jacek Glinka as president of its European division, the company said Thursday.

September 3, 2013

Indian regulators have approved a deal from Mylan to buy the injectables business of Strides Arcolab, Mylan said Tuesday.

August 14, 2013

In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr (epinephrine) Auto-Injectors to qualifying schools in the United States.

August 6, 2013

Mylan's sales ticked up slightly in second quarter 2013, compared with the same period last year, the company said.

June 24, 2013

Mylan Specialty has appointed Roger Graham as president, the Mylan subsidiary said Monday.

May 29, 2013

Mylan Specialty is extending a marketing campaign around its line of emergency treatments for severe allergic reactions.

April 25, 2013

Mylan Specialty announced Thursday the introduction of a "$0 Co-Pay Offer" on a product used to treat severe allergic reactions.